Mandate

Vinge assists Nuevolution in connection with Amgen’s cash offer

Vinge has assisted Nuevolution AB (publ) (“Nuevolution”) in connection with the cash offer to the shareholders in Nuevolution by Amgen Inc. (“Amgen”).

Nuevolution is a molecule drug discovery biotech company, listed on Nasdaq Stockholm. 

Amgen is one of the world’s leading biotechnology companies, with a vision deeply rooted in innovative science. Amgen’s shares are listed on Nasdaq in the United States.

Amgen offers SEK 32.50 in cash for every share in Nuevolution. The offer value amounts to approximately SEK 1,610 million.
 
Vinge’s team has primarily consisted of David Andersson, Dain Hård Nevonen, Ludvig Frithiof and William Kåge.

Related

Vinge has advised Triton in connection with sale of shares in Ambea AB (publ)

In total, 8.4 million shares were placed at a price of SEK 43.50 per share, corresponding to a total value of approximately SEK 365 million.
November 29, 2023

Vinge represents Lassie AB in a capital raising of SEK 260 million

Vinge has advised the pet insurance broker Lassie AB in connection with a capital raising of SEK 260 million in order to continue the expansion of the business.
November 29, 2023

Vinge advises Expedition Growth Capital in connection with its investment in Factbird 

Expedition Growth Capital, together with the Export and Investment Fund of Denmark (EIFO), have completed its investment in the Danish tech company Factbird. Vinge acted for Expedition Growth Capital in connection with the investment.
November 27, 2023